Abstract Title:

Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol.

Abstract Source:

Blood. 2010 Dec 9;116(24):5140-8. Epub 2010 Sep 8. PMID: 20826722

Abstract Author(s):

Qing-Shuo Zhang, Laura Marquez-Loza, Laura Eaton, Andrew W Duncan, Devorah C Goldman, Praveen Anur, Kevin Watanabe-Smith, R Keaney Rathbun, William H Fleming, Grover C Bagby, Markus Grompe

Article Affiliation:

Oregon Stem Cell Center, Department of Pediatrics, Oregon Health&Science University, Portland, OR, USA. [email protected]

Abstract:

Progressive bone marrow failure is a major cause of morbidity and mortality in human Fanconi Anemia patients. In an effort to develop a Fanconi Anemia murine model to study bone marrow failure, we found that Fancd2(-/-) mice have readily measurable hematopoietic defects. Fancd2 deficiency was associated with a significant decline in the size of the c-Kit(+)Sca-1(+)Lineage(-) (KSL) pool and reduced stem cell repopulation and spleen colony-forming capacity. Fancd2(-/-) KSL cells showed an abnormal cell cycle status and loss of quiescence. In addition, the supportive function of the marrow microenvironment was compromised in Fancd2(-/-) mice. Treatment with Sirt1-mimetic and the antioxidant drug, resveratrol, maintained Fancd2(-/-) KSL cells in quiescence, improved the marrow microenvironment, partially corrected the abnormal cell cycle status, and significantly improved the spleen colony-forming capacity of Fancd2(-/-) bone marrow cells. We conclude that Fancd2(-/-) mice have readily quantifiable hematopoietic defects, and that this model is well suited for pharmacologic screening studies.

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.